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SUMMARY
Human pluripotent stem cells (hPSCs) generate a
variety of disease-relevant cells that can be used to
improve the translation of preclinical research.
Despite the potential of hPSCs, their use for genetic
screening has been limited by technical challenges.
We developed a scalable and renewable Cas9 and
sgRNA-hPSC library in which loss-of-function muta-
tions can be induced at will. Our inducible mutant
hPSC library can be used for multiple genome-wide
CRISPR screens in a variety of hPSC-induced cell
types. As proof of concept, we performed three
screens for regulators of properties fundamental to
hPSCs: their ability to self-renew and/or survive
(fitness), their inability to survive as single-cell
clones, and their capacity to differentiate. We identi-
fied the majority of known genes and pathways
involved in these processes, as well as a plethora
of genes with unidentified roles. This resource will in-
crease the understanding of human development
and genetics. This approach will be a powerful tool
to identify disease-modifying genes and pathways.
INTRODUCTION
Human pluripotent stem cells (hPSCs) can be used to generate a
wide variety of disease-relevant cell types and have the potential
to improve the translation of preclinical research by enhancing
disease models. Despite the huge potential, genetic screening
using hPSCs has been limited by their expensive and tedious
cell culture requirements (Chen et al., 2011) and reduced genetic
manipulation efficiencies (Ihry et al., 2018). Only a few short
hairpin RNA (shRNA) screens have been conducted in hPSCs
(Chia et al., 2010; Zhang et al., 2013), but shRNAs have a high
level of off targets and do not cause a complete loss of function,
which is difficult to interpret (DasGupta et al., 2005; Echeverri
et al., 2006; Kampmann et al., 2015; McDonald et al., 2017).
Currently, the CRISPR/Cas9 system is the genetic screening
tool of choice because it can efficiently cause loss-of-function
alleles (Jinek et al., 2012; Cong et al., 2013; Mali et al., 2013).
Hundreds of genome-scale pooled CRISPR screens have been
performed in immortalized human cell lines (Hart et al., 2015;
Wang et al., 2015; Meyers et al., 2017). However, in hPSCs the
CRISPR/Cas9 system has been used primarily for small-scale
genome engineering (Merkle et al., 2015). In genetically intact
hPSCs, the only genome-scale CRISPR screen to date used
methods developed for cancer cells, suffered from technical is-
sues, had poor performance, and identified few developmentally
relevant genes (Hart et al., 2014; Shalem et al., 2014). We
addressed these technical issues by systematically tailoring
the CRISPR/Cas9 system for hPSCs (Ihry et al., 2018). We devel-
oped a doxycycline (dox)-inducible Cas9 (iCas9) hPSC line and
stably infected it with a genome-scale single guide RNA (sgRNA)
library. We banked and expanded the CRISPR-infected hPSC
library in the absence of editing (dox), which enabled us to
generate a renewable stem cell pool with stable but inactive
sgRNAs. This allowed us to conduct multiple independent
screens with the same cell library.
In thefirst screen,we identifiedgenes that suppressorenhance
hPSC fitness over long-term culture. Although previous screens
have generated gold-standard gene lists of core-essential genes
that reduce cell survival when mutated, little is known about the
mutations that enhance survival and proliferation. Unlike core-
essential genes, these enhancing mutations appear to be cell
type specific, and no consistent lists exist for this type of gene
(Hart et al., 2014). In hPSCs, karyotypic analysis has detected
recurrent copy number variations (CNVs) that confer a growth
advantage (Ampsetal.,2011;Laurentetal.,2011); however, these
studies lack gene level resolution. Recently, next-generation
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sequencing of hundreds of hPSCs identified the recurrence of
dominant-negative TP53 mutations that can expand within a
population of hPSCs (Merkle et al., 2017). We mined our data
for gene knockouts that enriched in culture and identified many
genes, including components of the TP53 pathway and other
known tumor suppressors. We validated the strongest hit,
PMAIP1/NOXA, which appears to be a stem cell-specific gene
conferring sensitivity to DNA damage downstream of TP53.
In the second screen, we identified genes required for single-
cell cloning. hPSCs have a poor survival rate after dissociation to
single cells, which is detrimental for genome engineering. Multi-
ple groups have extensively characterized death induced by sin-
gle-cell cloning and have demonstrated the process is similar to
but distinct from anoikis and is triggered by a ROCK/myosin/
actin pathway (Chen et al., 2010; Ohgushi et al., 2010). To pre-
vent death, hPSCs are passaged as clumps or treated with
ROCK inhibitors (Watanabe et al., 2007). By subjecting our
hPSCmutant library to single-cell dissociation without ROCK in-
hibitors, we selected for mutations that survive single-cell clon-
ing. sgRNAs for the ROCK and myosin pathways were enriched
in the surviving clones. The most enriched gene was the pro-
apoptotic regulator PAWR (Burikhanov et al., 2009). Validation
studies confirmed a role for PAWR as a component of the
actin-cytoskeleton that induces membrane blebbing and cell
death caused by single-cell cloning. The additional genes iden-
tified here will further our understanding about the sensitivity of
hPSCs to single-cell cloning.
In the final screen, we used a fluorescence-activated cell sort-
ing (FACS)-based OCT4 assay to identify regulators of pluripo-
tency and differentiation. Pluripotency is a defining feature of
hPSCs, and it allows them to differentiate into all three germ
layers.OCT4/POU5F1,NANOG, and SOX2 are critical transcrip-
tion factors that maintain pluripotency in vivo and in vitro (Nichols
et al., 1998; Chambers et al., 2007; Masui et al., 2007).OCT4 and
SOX2 overexpression is commonly used to reprogram somatic
cells toward the pluripotent state (Takahashi and Yamanaka,
2006; Takahashi et al., 2007; Yu et al., 2007). By isolating mutant
cells with high or low OCT4 protein expression, we identified
many genes involved in maintaining the pluripotent state, along
with genes involved with induction of differentiation.
By using an iCas9 hPSC line stably infected with a genome-
scale lentiCRISPR library, we were able to bank a CRISPR-
hPSC library that was renewable and enabled a large number
of independent screens with the same starting library. This
allows direct comparison between screens and reduces screen
to screen variability. We rigorously tested the system and identi-
fied genes important for fitness, single-cell cloning, and pluripo-
tency of hPSCs. Herein we provide a resource with detailed
methods and all available data including many genes that are
involved in hPSC biology. This resource will serve as a parts
list of genes that are functionally important for the human stem
cell state. These lists of genes provide unique insights into the
genetic regulation of human development that could only be
identified in normal diploid cells that are not transformed or
cancerous. Furthermore, the gene sets and methods will in-
crease our systematic knowledge of hPSC biology and will
enable additional large-scale CRISPR screens in stem cells
and their somatic derivatives.
RESULTS
The iCas9System Is aSelf-RenewingResourceEnabling
Successive Genome-wide Genetic Screens in hPSCs
We set out to develop a high-throughput CRISPR/Cas9 platform
for hPSCs that would enable successive rounds of screening
from a stable library of lentiCRISPR-infected hPSCs (Figures
1A and S1). Generating a genome-scale lentiCRISPR hPSC
library would enable both the rigorous testing of CRISPR screen
performance and the identification of cell type-specific regula-
tors of the pluripotent state. In our previous work, we developed
an all-in-one iCas9 transgene that was inactive in the absence of
dox (Ihry et al., 2018). The tight control over Cas9 expression al-
lowed us to transduce cells with lentiviruses expressing sgRNAs
(lentiCRISPRs) in the absence of dox without causing on-target
indels. We tested if it was possible to bank a genome-scale
lentiCRISPR-infected cell library (5 sgRNAs per gene, 91,725
total sgRNAs) prior to Cas9 mutagenesis (dox). After one
freeze-thaw cycle, next-generation sequencing (NGS) analysis
revealed no bottlenecking of the library demonstrating the feasi-
bility of banking a large lentiCRISPR hPSC library for repeated
screens (Figure 1B).
Evaluating the Performance of CRISPR Screening in
iCas9 hPSCs
Next, we performed a fitness screen to evaluate the global per-
formance of the system (Figure 1C). We benchmarked the per-
formance of the screen by using annotated lists of core-essential
genes. Core-essential genes are required for the survival of all
cells; the corresponding CRISPR knockout causes the sgRNAs
to be depleted (Hart et al., 2014, 2015). Genome-scale CRISPR
screening in hPSCs has been challenging (Hart et al., 2014; Sha-
lem et al., 2014). hPSCs have a strong DNA damage response
(DDR), and Cas9-induced double-strand breaks (DSBs) cause
a significant cell loss (Ihry et al., 2018). Failure to account for
Cas9-induced cell loss is problematic for pooled screening,
because it is critical to maintain representation of each sgRNA-
barcoded cell. Our previous work demonstrated a range of
Cas9-induced cells loss between 3- and 10-fold across many
sgRNAs (Ihry et al., 2018). To reduce the bottlenecking of the
sgRNA library caused by Cas9-induced toxicity, we started the
screen in hPSCs at an average of 1,200 cells per sgRNA (a total
of 110 million infected cells). By doing this we maintained about
4-fold more cells than a typical cancer screen (Hart et al., 2015).
During the fitness screen, DNA was sampled before and after
dox exposure at days 0, 8, 14, and 18 (Figure S1). To provide a
qualitative measurement of screen performance, we plotted
the p values calculated by the redundant small interfering RNA
(siRNA) activity (RSA) test against Q1 based Z scores for a set
of core-essential and non-essential genes (Ko¨nig et al., 2007;
Hart et al., 2014). Before dox treatment the non-essential and
core-essential genes are randomly distributed within a tight clus-
ter (Figure 1D). After 18 days of Cas9 treatment, the distribution
spreads, and the essential genes significantly drop out while the
non-essential genes remain constant (Figure 1D; Tables S1
and S2).
To quantify performance, we used the Bayesian analysis of
gene essentiality (BAGEL) algorithm, which calculates a Bayes
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92K Figure 1. A Self-Renewing Dox-Inducible
CAS9 Genome-wide sgRNA Cell Library En-
ables Multiple High-Performance CRISPR
Screens in Human Pluripotent Stem Cells
(A) Diagram depicting the iCas9 platform for
genome-scale CRISPR screening in hPSCs. The
iCas9 platform consists of a dox-inducible Cas9
transgene knocked in the AAVS1 locus of H1-
hESCs and lentiviral delivery of constitutively ex-
pressed sgRNAs. iCas9 hPSCs were transduced
(.5 MOI) at scale. After 1 week of expansion and
selection for lentiCRISPRs, iCas9 hPSCs were
either banked or subjected to Cas9 mutagenesis
for screening.
(B) Correlation of normalized sgRNA counts re-
veals that freeze and thaw expanded samples
(dox) have high correlation with the plasmid
library and the starting pool of infected iCas9
hPSCs at day 0 of the screen. Day 18 samples have
been exposed to dox (+Cas9). R2 values were
calculated on the basis of the normalized count
values.
(C) Diagram depicting three categories of genes
that enrich (enhance), deplete (suppress), or
remain constant during a fitness screen.
(D) Scatterplot depicting gene level results for
core-essential (pink) and non-essential (blue)
genes. Without Cas9 treatment (dox), cells ex-
pressing sgRNAs targeting core-essential and
non-essential genes are interspersed and have an
RSA > 2.75 (marked by dashed line). After
18 days of exposure to Cas9 (+dox), sgRNAs
targeting essential genes drop out to less than
RSA 2.75. The y axis is RSA value, and the x axis
marks the Z score (Q1). Non-essential and core-
essential gene list from Hart et al. (2014).
(E) Precision recall (PR) analysis of genome-scale
CRISPR screening data in H1-hESCs. Cas9-ex-
pressing cells (purple) exhibit a PR curve that
gradually slopes off, whereas cells without Cas9
(green) exhibit a PR curve that immediately de-
creases.
(F) Fitness gene calculation on the basis of 5%
false discovery rate (FDR) on the y axis. Each
condition labeled on the x axis.
(G) Venn diagram comparing 770 depleted genes
in hPSCs with 1,580 core-essential genes identi-
fied by screening cancer cell lines (Hart et al.,
2015). 405 of the hPSCs depleted genes overlap,
while the remaining 365 are specifically depleted in
pluripotent stem cells.
(H) Genes that dropout in CRISPR screen are
abundantly expressed. The y axis depicts the log2
transformation of average TPM values from 20 in-
dependent RNA-seq experiments in H1-hESC. For
each box blot, the median is depicted by white line
flanked by a rectangle spanning Q1–Q3. The x axis
depicts gene categories. In blue are non-essential
genes from Hart et al. (2014), in pink are 405 core-
essential genes, in purple are 365 stem cell-spe-
cific essential genes, and in gray are the remaining
unannotated genes.
See also Figure S1.
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factor for each gene by determining the probability that the
observed fold change for a given gene matches that of known
essential genes (Hart and Moffat, 2016).This generates a ranked
list of Bayes factors for each gene, which can then be used to
quantify screen performance by precision versus recall analysis.
In a high-performance screen, essential genes have high Bayes
factor scores, and the precision versus recall curve gradually
drops off as analysis of the ranked list is completed. In contrast,
a poor-performing screen has a precision versus recall curve that
rapidly drops off, indicating many false positives (non-essential
genes) with high Bayes factor scores. The sample without dox
exposure (untreated) has a randomly ranked Bayes factor list
with non-essential and essential genes interspersed and exhibits
a poor precision versus recall curve (Figure 1E). In the day 18
Cas9 (+dox) treated samples, essential genes and non-essential
genes segregate from each other and generates a high-perform-
ing precision versus recall curve that gradually drops off (Fig-
ure 1E; Table S3).
After 18 days of Cas9 exposure, we identified 770 fitness
genes at a 5% false discovery rate on the basis of the precision
calculation (Figure 1F; Table S4). Comparing the set of 770 hPSC
fitness genes with 1,580 core-essential genes from cancer lines
revealed an overlap of 405 genes (Figure 1G) (Hart et al., 2015).
The remaining 365 specifically dropped out in hPSCs. Both the
core and hPSC-specific essential genes are abundantly ex-
pressed in hPSCs, further supporting that they are required to
maintain hPSCs in culture (Figure 1H). Our fitness screen in
hPSCs correctly identifies the dropout of core-essential genes
with accuracy that is on par with CRISPR screens conducted
in cancer cell lines. This demonstrates that cancer cells and
stem cells share a common set of core-essential genes that
can be used to benchmark performance. By accounting for
cell loss caused by Cas9 activity, we limited the effects of
Cas9-induced toxicity that have thwarted previous attempts at
genome-scale screening in hPSCs (Hart et al., 2014; Shalem
et al., 2014). This demonstrates that it is possible to conduct
an effective genome-scale CRISPR screen in hPSCs using the
methods described here.
TP53 Pathway Mutations Specifically Enrich during
CRISPR Fitness Screen in hPSCs
Curated lists of genes that enhance fitness during a CRISPR
screen do not exist, making it difficult to benchmark the
enrichment results (Hart et al., 2015). By comparing the top
1,000 depleted (RSA-down < 2.25; Table S2) and enriched
(RSA-up < 2.25; Table S5) genes, we observed that 31.8%
(301 of 946) of the enriched genes were located on the X and Y
chromosomes (H1-human embryonic stem cells [hESCs] XY;
Figure S3). In contrast, the depleted genes were evenly distrib-
uted across all chromosomes. It became apparent that
allosome-targeting sgRNAs were behaving similarly to non-tar-
geting controls, which enrich during a CRISPR screen in hPSCs
(Ihry et al., 2018). We observed that sgRNAs causing a single
DSB on the X chromosome are less toxic relative to sgRNAs
inducing two DSBs at the MAPT locus despite being able to
efficiently induce indels (Figure S2). sgRNAs targeting genomic
amplifications in cancer cell lines exhibit a strong depletion irre-
spective of the gene targets (Aguirre et al., 2016; Munoz et al.,
2016; Meyers et al., 2017). Unlike cancer cell lines, H1-hESCs
with a normal diploid karyotype are very sensitive to DNA dam-
age, making the difference between one and two DSBs signifi-
cant. After recognizing that the enrichment of sgRNAs on the
X and Y chromosomes was related to DSB sensitivity and copy
number differences in male H1-hESCs, we focused on auto-
somal genes. In the remaining list of 645 autosomal genes that
were enriched (RSA-up 2.25), we identified 41 tumor suppres-
sor genes (Zhao et al., 2016).
The secondmost enriched genewas TP53, which confirms the
selective pressure imposed by Cas9-induced DSBs in hPSCs
during a CRISPR screen (Figure 2A). Consistent with this TP53
mutants are able to suppress cell loss induced by Cas9 activity
(Ihry et al., 2018). Throughout the 18-day screen, the representa-
tion of sgRNAs targeting TP53 (chromosome [Chr.] 17), the
checkpoint kinase CHEK2 (Chr. 22), and the pro-apoptotic regu-
lator PMAIP1 (Chr. 18) increased in a time-dependent manner
(Figure 2B). Database mining for associations with TP53 among
the enriched genes identified 20 genes with direct connections
to TP53 (Figure 2C; Table S6), 19 of which are expressed in
H1-hESC and are on autosomal chromosomes. Although
EDA2R is on the X chromosome, it was included because its
mRNA increases in response to DNA damage in hPSCs (Ihry
et al., 2018). We hypothesized that these genes could include
additional regulators responsible for the extreme sensitivity to
DNA damage in hPSCs.
PMAIP1 was the most enriched gene in the screen. PMAIP1
has been implicated in TP53-dependent cell death and functions
by sensitizing cells to apoptosis by antagonizing the anti-
apoptotic protein MCL1 at the mitochondria (Kim et al., 2006;
Ploner et al., 2008; Perciavalle et al., 2012). PMAIP1 is highly ex-
pressed in hPSCs, and its expressionmarks the pluripotent state
(Mallon et al., 2013). We confirmed this by examining PMAIP1
expression in two induced pluripotent stem cell (iPSC) and two
hESC lines. Analysis of RNA sequencing (RNA-seq) experiments
confirmed that PMAIP1 was highly expressed during the plurip-
otent state and drops during neuronal differentiation using the
NGN2 transgene (Figure 3A). Additionally, Genotype-Tissue
Expression (GTEx) data revealed that PMAIP1 has a highly
restricted expression pattern and is not expressed in most
tissues (GTEx Analysis Release V7). Although it has been
demonstrated that PMAIP1 expression is maintained by OCT4
in testicular germ cell tumors (Gutekunst et al., 2013), no func-
tional connection has beenmade in hPSCs.We tested if PMAIP1
expression was maintained by the pluripotency network by
differentiating cells or knocking out OCT4. Under these condi-
tions qPCR detected a significant decrease in PMAIP1 mRNA
(Figure 3B). In thymocytes, PMAIP1 mRNA is induced by TP53
(Khandanpour et al., 2013). We knocked out TP53 in hPSCs
but did not detect a reduction in PMAIP1 mRNA (Figure 3B).
hPSCs constitutively express high levels of PMAIP1, and DNA
damage does not increase PMAIP1 expression, further support-
ing PMAIP1 mRNA as pluripotency dependent and TP53 inde-
pendent (Ihry et al., 2018).
Prior work demonstrated that cancer cell lines have a reduced
DDR relative to hPSCs (Ihry et al., 2018). Consistent with this, we
did not observe an enrichment of PMAIP1 sgRNAs in 14 inde-
pendent CRISPR screens conducted in cancer cell lines despite
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using libraries containing the same PMAIP1-targeting sgRNAs
(Figure 3C). This suggested that PMAIP1 is responsible for
making hPSCs sensitive to DNA damage. To test the functional
consequences of PMAIP1 mutations, we knocked out PMAIP1
in the iCas9 cell line using transient exposure to synthetic
crRNAs (Figure S3). We tested if PMAIP1mutants were resistant
to DSB-induced death by using lentiCRISPRs to deliver a sgRNA
targetingMAPT, a neuronal gene not expressed in hPSCs. In the
absence of Cas9 (dox), both control and PMAIP1mutant iCas9
cells grow at a similar rate while expressing an sgRNA. In the
presence of Cas9 (+dox) and a sgRNA, control cells die, while
PMAIP1mutants are able to survive despite efficient DSB induc-
tion (Figures 3D, S3, and S4E). qPCR analysis of the TP53-target
genes P21 and FAS detected an elevated expression in PMAIP1
mutants compared with controls (Figure 3E). Despite having an
active TP53, PMAIP1 mutants survive. This indicates PMAIP1
is downstream of TP53 activation and is consistent with its
known role as a sensitizer to apoptosis (Ploner et al., 2008). In
hPSCs, cell death is the predominant response to DNA damage.
Unlike PMAIP1 mutants, P21 mutants (>80% indels) are unable
to suppress DSB-induced toxicity (Figure S4E), andP21 sgRNAs
did not enrich in H1-hESCs. In contrast, in a genome-scale
screen in retinal pigment epithelial cells, where Cas9 activity
causes TP53-dependent cell-cycle arrest rather than apoptosis,
sgRNAs targeting TP53 and P21/CDKN1A were enriched, while
PMAIP1 sgRNAs were not (Table S5) (Haapaniemi et al., 2017).
Overall, these results indicate that PMAIP1 plays a role in the
sensitivity of hPSCs to DNA damage and highlight the ability of
genome-scale CRISPR screens to identify cell type-specific
genes important for the fitness of pluripotent stem cells.
Genetic Screen for Suppressors of Dissociation-
Induced Death
We next tested our ability to identify phenotypic regulators of hu-
man developmental processes. Human PSCs, unlike mouse
PSCs, are very sensitive to dissociation and die in the absence
of ROCK inhibitors (Ohgushi et al., 2010). During dissociation
of hPSCs, Rho and ROCK become activated. This leads to the
phosphorylation of myosin, which causes membrane blebbing
and cell death. To promote survival, inhibitors that target
ROCK (Y-27632 or thiazovivin) or myosin (blebbistatin) are
used routinely during hPSC passaging (Watanabe et al., 2007;
Chen et al., 2010). Very few cells survive dissociation in the
absence of ROCK inhibitors. Importantly, this phenotype is
developmentally rooted. hPSCs are epiblast-like, and cells that
fail to incorporate into the polarized epithelium of the epiblast un-
dergo cell death in the embryo (Ohgushi et al., 2010). To gain a
deeper understanding of the genes involved, we screened for
suppressors of dissociation-induced death.
To ensure complete Cas9 mutagenesis, we waited till the day
14 passage of the fitness screen to plate an additional replicate
of the genome-scale mutant cell library in the absence of thiazo-
vivin (Figures 4A and S1). The majority of the mutant cells died
during this process, and the surviving cells were maintained for
2 weeks until large colonies were visible, at which point DNA
was isolated and sgRNAs sequences were recovered by NGS.
We identified 76 genes with two or more independent sgRNAs
present in cells that survived dissociation without thiazovivin
A
B
C
Figure 2. TP53 Pathway Mutations Enrich during CRISPR Screen in
hPSCs
(A) Scatterplot depicting gene-level results for the genome-scale screen.
After 18 days of exposure to Cas9 (+dox), sgRNAs targeting TP53-related
genes enrich during the screen; PMAIP1 (NOXA) (RSA 10.6, Q3 3.7), TP53
(RSA 7.64, Q3 4), and CHEK2 (RSA 3.6, Q3 2.4). A total of 302 genes have
RSA scores < 3 (marked by dashed line). TP53-related genes with RSA
scores <2.25 are marked in red. The y axis is a p value generated from RSA-
up analysis. The x axis marks the Z score (Q3).
(B) Plot showing the time-dependent increase in five independent sgRNAs
targeting PMAIP1, CHEK2, and TP53 during CRISPR screen. NGS quantifies
representation of lentiCRISPR-infected cells. Samples were normalized to the
day 0 population. The y axis represents log2(fold change). Day 0 data shown
are from freeze and thaw samples. The x axis plots each condition over time.
Cas9+ samples were treated with dox to induce Cas9 expression.
(C) Shown are gene knockouts (20) that enrich during CRISPR screen that are
connected to TP53 and play roles in either DNA damage response and
apoptosis. 946 enriched genes in RSA-up < 2.25 identified by STRINGdb
analysis.
See also Figures S1 and S2.
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(Figure 4C; Table S7). As expected, multiple sgRNAs targeting
ROCK1 and MYH9, the genetic targets of ROCK inhibitors and
blebbistatin, were recovered. Myosin is a hexameric motor pro-
tein that is composed of six subunits with three subtypes. The
screen recovered three sgRNAs for MYH9, a myosin heavy
chain, five sgRNAs forMYL6, a non-phosphorylated myosin light
chain, and two sgRNAs for the ROCK target MYL9/MLC2, a
phosphorylated myosin light chain. There are many myosin
proteins, but our screen identified three of five of the most
abundantly expressed in hPSCs (Figure 4B). This reiterates the
importance of myosin activation in membrane blebbing and
dissociation-induced death. A number of additional genes
have roles in the actin and myosin network or cytoskeleton,
including DAPK3, PAWR, OPHN1, FLII, and KIF3A (Figure 4D).
Overall STRINGdb analysis detected a connected set of genes
with ties to the actin and myosin regulatory network (Figure 4D).
In general members of this network did not enrich during the
fitness screen, suggesting that they specifically regulate dissoci-
ation-induced death and not fitness (Figure 4E).
PAWR Is Required for Dissociation-Induced Death
For follow-up studies, we focused on the strongest hit from the
screen, the pro-apoptotic regulator PAWR (Hebbar et al.,
2012). PAWR has no known biological role in the early embryo
or during dissociation-induced death of hPSCs. The screen
recovered all five sgRNAs targeting PAWR in the genome-scale
library, and the barcode reads were highly abundant (Figure 4C).
Unlike sgRNAs for the TP53 pathway that enrich throughout the
CRISPR screen,PAWR andMYL6 have no effect on fitness in the
presence of thiazovivin (Figure 4E). We repeated the results us-
ing three independent lentiCRISPRs to knock out PAWR in
iCas9 expressing H1-hESC cells. PAWRmutants are able to sur-
vive without thiazovivin, while control cells do not (Figure S4). To
independently validate these results, we used CRISPR-medi-
ated interference (CRISPRi) to knock down the expression of
PAWR mRNA without causing DNA damage or genetic muta-
tions (Data S1) (Qi et al., 2013). By using a H1-hESC line consti-
tutively expressing dCas9 fused to a KRAB domain and sgRNAs
targeting PAWR promoter, we also detected an increase in the
survival of dissociated cells in the absence of thiazovivin
(Figure S4).
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Figure 3. PMAIP1 Confers Sensitivity to DNA Damage in hPSCs
(A) PMAIP1 is highly expressed in hESCs and iPSCs. The y axis represents
expression in transcripts per kilobase million (TPM). H1-hESCs (n = 1),
H9-hESCs (n = 3), 8402-iPSCs (n = 3), and HDFn-iPSCs (n = 4). The x axis
represents days after induction of a doxycycline-inducible NGN2 expression
cassette. Day 0 = hPSCs.
(B) qPCR confirms that PMAIP1 mRNA is dependent on the pluripotent state.
The y axis is relative expression, and each bar represents mean relative
expression. The x axis is each condition. Control, hPSCs in E8 media; +FBS,
3 days’ exposure to 10% fetal bovine serum (FBS) and DMEM; +NGN2, 3 days’
exposure to NGN2;OCT4KO, mutant pool after 6 days’ exposure to iCas9 and
sgRNA targeting OCT4; PMAIP1/, complete knockout cell line; TP53/,
complete knockout cell line. n = 3 independent mRNA samples per sgRNA,
error bars indicate ±1 SD. *p < 0.05 and **p < 0.01 (unpaired two-tailed t test,
equal variances).
(C) PMAIP1-targeting sgRNAs specifically enrich during CRISPR screen in
hESC but not cancer cell lines. The x axis plots CRISPR screens conducted in
H1-hESC lines and 14 additional transformed lines. Five independent sgRNAs
marked by dots. The y axis represents log2(fold change).
(D) PMAIP1 mutant hPSCs are insensitive to DNA damage. Live imaging of
confluence in MAPT sgRNA expressing iCas9 cells ± DSB (+dox/Cas9) in
control or PMAIP1/ knockout cell line. Unlike DSB-treated control cells, the
PMAIP1/ mutants survive in the presence of DSBs. Black lines indicate
control andmagenta lines indicate PMAIP1/mutants. Solid lines are without
dox, and dashed lines are cultured with dox. The y axis is percentage con-
fluency each point represents mean (four images per well, n = 3 wells). Error
bars indicate ±1 SD. The x axis depicts time in days of treatment.
(E) qPCR of TP53 target genes indicates PMAIP1 functions downstream of
TP53. P21 and FAS mRNA is induced by MAPT targeting sgRNAs in iCas9
control cells 2 days after dox treatment. PMAIP1/mutants exhibit increased
levels of P21 and FASmRNA, which is absent in TP53/mutants. The y axis is
relative expression is calculated by comparing theMAPT targeting sgRNAplus
(+dox) or minus Cas9 expression (dox). *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001 (unpaired two-tailed t test, equal variances). Error bars ± 1 SD.
See also Figures S1, S3, and S5.
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Figure 4. Genetic Screen for Suppressors of Dissociation-Induced Death
(A) Diagram depicting screen shows the dissociation and replating of the genome-scale mutant cell library without thiazovivin (a ROCK inhibitor). Most cells did
not survive the treatment; however, at the end of 2 weeks, some large colonies were recovered for DNA isolation and NGS analysis.
(B) The screen recovered three of six subunits of the hexameric myosin motor protein that regulates blebbing in hPSCs. The y axis depicts average TPM in
H1-hESC. The x axis depicts myosin genes expressed >1 TPM in H1-hESCs. Myosin genes recovered by screen in pink. Genes that were not detected by screen
are in blue.
(C) Heatmap depicting number of sgRNAs recovered on the y axis and each gene on the x axis. Colors indicate the abundance of each sgRNA recovered. Pink
marks greater than 90th percentile, and purple marks less than 10th percentile.
(D) STRINGdb analysis highlights actin andmyosin gene network among mutations that allow cells to survive dissociation in the absence of ROCK inhibitors. Hits
from screen marked in green.
(E)MYL6 and PAWR specifically regulate survival after dissociation and do not enrich during CRISPR screen. Each dot represents five independent sgRNAs per
gene, and NGS quantifies representation of lentiCRISPRs infected cells. Samples were normalized to the day 0 population and y axis represents log2(fold
change). Day 0 data shown is from freeze and thaw samples maintained at 2,7003. The x axis plots each condition over time. Cas9+ samples were treated with
dox to induce Cas9 expression.
See also Figures S1, S4, and S6.
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To conduct detailed analysis of PAWR mutants, we exposed
cells to Cas9 and sgRNAs targeting PAWR and generated a
knockout cell line with a normal karyotype (Figure S4). The
suppression of dissociation-induced death is specific to
PAWR mutants, as PMAIP1 mutants are unable to survive
passaging without thiazovivin (Figures 5A and 5B). Conversely,
PAWR mutants are unable to survive DSB-induced toxicity,
further demonstrating the specificity of the respective pheno-
types (Figure S4E). We next examined how PAWR mutants
survive by time-lapse microscopy. After single-cell dissocia-
tion, control cells without thiazovivin exhibit membrane bleb-
bing and subsequently die (Figure 5C). Conversely, PAWR
mutants without thiazovivin have greatly reduced blebbing
and survive as single cells by extending cell projections, which
promote attachment and survival (Figure 5C). We further
examined cytoskeletal organization using phalloidin to stain
filamentous (F) actin. The thiazovivin-treated cells have an
increased surface area, a fanned-out shape with actin stress
fibers, and a large circular adhesion belt-like structure (Fig-
ure 5C). In the absence of thiazovivin, control cells have
many small actin rings that mark membrane blebs. PAWR mu-
tants without thiazovivin exhibit reduced membrane blebbing
and small actin rings (Figure 5C).
Molecularly, PAWR has dual roles as a transcriptional
repressor that causes cell death and as an actin-binding pro-
tein that regulates contractility (Johnstone et al., 1996; Buri-
khanov et al., 2009; Vetterkind and Morgan, 2009). Despite
having abundant PAWR mRNA, PAWR protein is post-tran-
scriptionally regulated and induced by dissociation in hPSCs
(Figures S4 and S5). Immunofluorescence did not detect
PAWR protein in the nucleus; however, we did observe locali-
zation of PAWR with F-actin in both thiazovivin-treated and un-
treated cells (Figure 5D). PAWR localized to adhesion belt-like
structures in the presence of thiazovivin and to membrane
blebs in the untreated cells after dissociation. Additional hits
from the screen, PRKCZ and SCRIB, also localized to
membrane blebs (Figure S6). Both PRKCZ and SCRIB are ex-
pressed in the early mouse embryo and exhibit a ROCK-
dependent cell polarity (Kono et al., 2014). Cumulatively, we
have identified a role for PAWR in dissociation-induced death.
PAWR mutants survive dissociation without ROCK inhibitors
because of a failure to initiate membrane blebbing and down-
stream caspase activation (Figure S5) (Ohgushi et al., 2010).
Furthermore, PAWR is a known pro-apoptotic factor, and we
have demonstrated that PAWR protein is induced upon disso-
ciation and colocalizes with the actin network that is respon-
sible for initiating membrane blebbing and subsequent cell
death.
FACS-Based Screen for Regulators of Pluripotency
Although our fitness screen detected a significant hPSC-specific
dropout ofOCT4, other critical regulators of pluripotency such as
NANOG did not affect fitness (Figure 1E; Table S4). A genome-
scale fitness screen in mouse embryonic stem cells (mESCs)
had similar results and reported the dropout of only three genes
regulating blastocyst development (Koike-Yusa et al., 2014). Plu-
ripotency and cellular fitness of hPSCs may not be related, and
this indicates that some differentiated cell types may not exhibit
changes in fitness when cultured in the pluripotent media. To
specifically identify regulators of human pluripotency, we con-
ducted a FACS-based pooled screen using an OCT4 antibody.
One year after conducting the first screen, we thawed a
genome-scale CRISPR cell library (dox) and expanded the
cells prior to conducting the screen (Figure S1). The cells were
mutagenized with Cas9 for 8 days prior to FACS to collect cells
with high (OCT4HIGH) and low (OCT4LOW) OCT4 expression (Fig-
ure 6A). Log2(fold change) was calculated by comparing the
OCT4LOW group with the OCT4HIGH group. We plotted the
p values calculated by the RSA test against Q1- and Q3-based
Z scores for OCT4LOW and OCT4HIGH, respectively (Figure 7B;
Table S8). Importantly, we detected a significant enrichment of
OCT4 and NANOG targeting sgRNAs in the OCT4LOW group.
We also detected an enrichment of TGFBR1/2 genes required
to maintain the culture of hPSCs and the chromatin regulators
EP300 and SMARCA4/BRG1, which regulate OCT4 expression
and function in hPSCs (Singhal et al., 2010; Chen et al., 2011;
Wang et al., 2012; King and Klose, 2017). Using STRINGdb,
we identified a core network of genes connected to OCT4 in
the OCT4LOW group (Figure 6C). This highlights the ability of
phenotypic CRISPR screening to identify relevant gene net-
works. Additionally, the OCT4HIGH group identified factors that
promote differentiation, such as HAND1, KDM5B, and EIF4G2
(Table S8) (Yamanaka et al., 2000; Hough et al., 2006; Kidder
et al., 2013). Many of the genes in these lists have published roles
in regulating pluripotency, reprogramming or embryonic devel-
opment, and further investigation of the less studied genes will
reveal insights into the human pluripotent state (Tables S8
and S9).
Figure 5. PAWR Is Required for Dissociation-Induced Death
(A) PAWRmutants survive single-cell dissociation in the absence of thiazovivin (a ROCK inhibitor) treatment. Control cells and PMAIP1 knockout do not survive
without thiazovivin treatment. Bright-field images taken of live iCas9 cells 4 days after dissociation. Scale bar, 800 mM.
(B) Quantification of survival in the presence or absence of thiazovivin. Percentage confluence wasmeasured 4 days after replate in control, PAWR knockout, and
PMAIP1 knockout cells. Bars represent mean from three independent wells with four images per well. Error bars indicate ±1 SD from four images per well from
three independent wells. The dissociation-induced survival of PAWR mutant hPSCs was replicated more than three times.
(C) Time-lapse microscopy of live cells during first 9 h of replate. Control and PAWR knockout hPSCs survive replating in the presence of thiazovivin by extending
cellular projections and forming an actin adhesion belt organized with stress fibers. Phalloidin stain at 3.5 h in fixed cells. Control cells without thiazovivin have
abundant membrane blebbing, and this is highlighted by the presence of small circular actin rings in phalloidin stained cells. PAWR mutants have reduced
blebbing and intermediate phalloidin staining without small actin rings. Scale bar, 50 mM.
(D) Immunofluorescence detects PAWR protein colocalizing with F-actin. Following dissociation, PAWR protein colocalizes with F-actin in the presence of
thiazovivin in adhesion belt-like structures and in the absence of thiazovivin in membrane blebs. Green indicates PAWR protein. Magenta indicates phalloidin-
stained F-actin. Blue indicates DAPI-stained nuclei. Scale bar, 50 mM.
See also Figures S1, S4, and S5.
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Identification of hPSC-Specific Fitness andPluripotency
Gene Networks
Extensive CRISPR screening in cancer cell lines has provided
a wealth of knowledge about their genetic dependencies. How-
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Figure 6. OCT4 FACS-Based Screen Iden-
tifies Pluripotency Gene Network
(A) Diagram depicting FACS-based CRISPR
screen using an OCT4 specific antibody to sort
OCT4 high- and low-expressing cells. Cells were
mutagenized with Cas9 for 8 days prior to FACS
sorting, and DNA isolation and NGS were used to
identify enrichment of sgRNAs in the high- and
low-OCT4 populations.
(B) Scatterplot depicting gene level results for
genome-scale OCT4 FACS screen. Green depicts
OCT4LOW and gold depicts OCT4HIGH enriched
sgRNAs. The y axis is a p value generated from
RSA down and up analysis. The x axis marks the
Z score (Q1/Q3).
(C) STRINGdb analysis identifies a 20-gene
network connected to OCT4 among gene sgRNAs
that were enriched in cells with low OCT4 protein.
Genes with published roles in pluripotency,
reprogramming, and embryo development are
highlighted in green.
See also Figure S1.
ever, the static state of these cells has
revealed less about genes with develop-
mental functions (Hart et al., 2015). To
compare hPSC results to cancer cell
lines, we conducted pairwise Pearson
correlation coefficients using Bayes fac-
tor distributions (cancer data from Hart
et al., 2015). The analysis revealed that
hPSCs formed a distinct cluster (Fig-
ure 7A) and is consistent with the partial
overlap between core-essential genes in
cancer and fitness genes in hPSCs
(52%; Figure 1E). To focus on gene net-
works specific to hPSCs, we conducted
bioinformatics analysis comparing 829
core-essential cancer genes (essential
for five of five cell lines; Hart et al., 2015)
with hPSC-specific gene sets identified
by our screens. A total of 661 hPSC-spe-
cific genes were obtained from the fitness
screen (365 depleted and 20 enriched
p53-related genes), dissociation-induced
death screen (76), and the OCT4 FACS
screen (212) (Table S10). The gene lists
were analyzed using the PANTHER
classification system (pantherdb.org).
PANTHER pathway analysis identified a
greater diversity of 92 enriched pathways
in hPSCs and only 38 in the cancer lines
(Figure 7B). In accordance with this, we
also detected an increase in the number
of genes with receptor and signal trans-
ducer activity molecular functions (Figure 7C). The hPSC-
enriched pathways included several expected regulators:
FGF, TGF-beta, and WNT (Figure 7B). FGF2 and TGFb are crit-
ical components of E8 media and are required to maintain
Cell Reports 27, 616–630, April 9, 2019 625
pluripotency in vitro (Chen et al., 2011). WNT signaling regulates
both differentiation and pluripotency in ESCs (Sokol, 2011). Acti-
vation of EGF, PDGF, and VEGF is also important for the mainte-
nance of the pluripotent state in (Figure 7B) (Brill et al., 2009). P53
and CCKR/Rho GTPases pathways, which regulate apoptosis
and have critical roles in determining the sensitivity of hPSCs
to DNA damage and enzymatic dissociation, were also enriched
(Figure 7B). Examination of the biological processes’ gene
ontology revealed an increase in the number of development
and multicellular organism genes (Figure 7C). Furthermore,
sub-dividing the developmental process category revealed
enrichment of genes regulating cell death, differentiation, and
early developmental stages (Figure 7C). Globally these results
highlight the identification of cell type-specific genes regulating
different aspects of the pluripotent state. By screening for regu-
lators of three fundamental processes governing the culture of
hPSCs, we have successfully identified known regulators in
addition to a plethora of genes involved in stem cell biology
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Figure 7. Identification of hPSC-Specific Essential Gene Networks
(A) Heatmap of Pearson correlation coefficients adapted from Hart et al. (2015) to include CRISPR screening data in H1-hESCs.
(B) PANTHER pathway analysis identified 92 enriched pathways in hPSCs. A subset of 15 hPSC-specific pathways are depicted.
(C) Depiction of Gene Ontology categories including biological processes, molecular functions, and developmental processes that are specific to hPSCs but not
cancer cell lines.
(D) Schematic of genes identified by CRISPR screening in hPSCs and their putative functions. Seven hundred seventy fitness genes regulate the self-renewing
potential of hPSCs. One hundred thirteen genes with low OCT4 protein are implicated in pluripotency, and 99 genes with increased OCT4 protein may promote
differentiation. Twenty genes are implicated in the toxic response to DNA damage. Seventy-six genes are implicated in the sensitivity of hPSCs to single-cell
dissociation. (B–D) Bioinformatic analysis of 829 core-essential cancer (white bars; Hart et al., 2015) and 653 hPSC-specific genes (green bars). Genes in multiple
categories are shown in blue.
See also Figure S1.
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(Figure 7D). These genes are a blueprint for human pluripotency
and will serve as a useful resource for the human development
and stem cell communities.
DISCUSSION
The use of hPSCs in large-scale functional genomics studies has
been limited by technical constraints. Prior to our study, it was
unclear that genome-scale CRISPR screens were possible in
hPSCs, as the first attempts had poor performance (Hart et al.,
2014; Shalem et al., 2014). We overcame this by building a
high-performance two-component CRISPR/CAS9 system for
hPSCs. The performance, across many sgRNAs, made the plat-
form amenable to high-throughput screening. Using iCas9 in
hPSCs it is possible to perturb hundreds of genes in arrayed
format or the entire genome in pooled format. The system is
renewable, and a pool of stem cells with sgRNAs to the entire
genome can be banked, distributed, and used for successive
screens in hPSCs and their differentiated progeny. Beyond tech-
nical proficiency, we identified genes that regulate fundamental
stem cell processes such as self-renewal, their inherent sensi-
tivity to DNA damage, single-cell cloning, pluripotency, and
differentiation.
First, we identified 770 genes required for the self-renewal of
hPSC. A majority of these genes have established roles in
fitness, while 365 of these genes are specific to hPSCs. This
set of genes could be used to inform a systematic approach to
improve the consistency, robustness, and user-friendliness of
hPSC culture conditions. During the fitness screen, we also
determined that Cas9 activity imposes selective pressure on
DNA damage-sensitive hPSCs. This caused the enrichment of
20 genes that are connected to TP53. Consistent with this, domi-
nant-negative TP53 mutations and deletions recurrently occur
and provide a selective advantage during the culture of hPSCs
(Amir et al., 2017; Merkle et al., 2017). In addition to TP53, we
identified a hPSC-specific role for PMAIP1 in determining the
extreme sensitivity of hPSCs to DNA damage. Like TP53, dele-
tions of chromosome 18 spanning the PMAIP1 locus have
been recurrently observed during hPSC culture (Amps et al.,
2011) and suggest that PMAIP1 deletion may be responsible
for enhanced survival of these lines. These TP53-related genes
have the potential to improve the efficiency or safety of genome
engineering through transient inhibition or by monitoring their
spontaneous mutation rate during hPSC culture (Merkle et al.,
2017; Ihry et al., 2018).
Second, we identified 76 genes that enhance the survival of
hPSCs during single-cell dissociation. Collectively, the screen
uncovered an actin and myosin network required for membrane
blebbing and cell death caused by dissociation. We identified a
role for PAWR, a pro-apoptotic regulator that is induced upon
dissociation. PAWR is required for membrane blebbing and sub-
sequent death of dissociated hPSCs in the absence of ROCK in-
hibitors. Importantly, the results are developmentally relevant,
and we also identified SCRIB and PRKCZ, which are known reg-
ulators of cell polarity in the early mouse embryo (Kono et al.,
2014). PAWR has been shown to physically interact with PRKCZ
and suggests a potential link between cell polarity and dissocia-
tion-induced death (Dı´az-Meco et al., 1996). These hits appear to
be related to the polarized epiblast-like state of primed hPSC
and could explain why polarized hPSCs are sensitive to dissoci-
ation, whereas unpolarized naive mESCs are not (Takashima
et al., 2015). Last, this set of genes could enable focused ap-
proaches to improve the single-cell cloning efficiencies of hPSCs
and the culture of naive hPSCs.
In the final screen, by subjecting our hPSC CRISPR library to
FACS sorting on OCT4 protein, we identified 113 genes that
are required to maintain pluripotency and 99 genes that poten-
tially regulate differentiation. Overall, the screen identified an
entire network of genes related to OCT4. Nineteen of these
genes have previously indicated roles in pluripotency, embryo
development, and reprogramming (Table S9). Future studies
on the genes in the list will yield new insights about the genetic
control of pluripotency and differentiation. These gene sets
could guide rational improvements to protocols for the mainte-
nance, differentiation, and reprogramming of hPSCs.
Overall, the results highlight the ability of unbiased genome-
scale screens to identify critical and regulators of hPSC biology.
Importantly, some of the strongest hits, such as PAWR and
PMAIP1, were also identified in haploid hPSC screens (Yilmaz
et al., 2018). Future investigation into the genes provided by
these screens will be a step toward the genetic dissection of
the human pluripotent state. Herein we provide simple and
scalable work flows that will lower the entry barrier for additional
labs to conduct large-scale CRISPR screens in hPSCs. The scal-
able and bankable platform described here is a renewable
resource that will allow successive screens and the distribution
of CRISPR-infected hPSC libraries. We anticipate that the use
of CRISPRi will improve the performance. Reducing Cas9-
induced toxicity will limit artifacts and reduce need for high li-
brary coverage and costs to enable systematic screening in
many independent hPSC lines and differentiated cell types.
The platform could potentially be used to improve the genera-
tion, culture, and differentiation capacity of hPSCs. It can be
applied to the study of development and disease in wide variety
of differentiated cell types. Established protocols for neurons,
astrocytes, cardiomyocytes, hepatocytes, and beta cells can
be exploited to dissect the genetic nature of development and
homeostasis in disease-relevant cell types. This resource opens
the door for the systematic genetic dissection of disease-rele-
vant human cells in way that was only before possible in model
organisms.
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Antibodies
Conjugated (AF488) Rabbit anti-OCT4 (C30A3) Cell Signaling Technologies CST-5177; RRID:AB_10693303
Phallodin-647 ThermoFisher Scientific A22287; RRID:AB_2620155
Rabbit anti-scribble (SCRIB) Abcam ab36708; RRID:AB_777865
Rabbit anti-PKC zeta (PRKCZ) Abcam ab59364; RRID:AB_944858
Rabbit anti-PAR-4 (PAWR) Cell Signaling Technologies CST-2328; RRID:AB_561235
Rabbit anti-Cleaved Caspase-3 Asp175 (CC3) Cell Signaling Technologies CST-9661; RRID:AB_2341188
Mouse anti-GAPDH (ID4) Enzo ADI-CSA-335-E; RRID:AB_2039148
IRDye 800CW anti-rabbit LiCOR 926-32211; RRID:AB_621843
IRDye 680RD anti-mouse LiCOR 926-68070; RRID:AB_10956588
Chemicals, Peptides, and Recombinant Proteins
thiazovivin Selleckchem S1459
Experimental Models: Cell Lines
Human: H1-hESCs, NIHhESC-10-0043, WA01 (XY) WiCell H1-hESCs
Human: H9-hESCs, NIHhESC-10-0062, WA09 (XX) WiCell H9-hESCs
Human: 8402-iPSCs (XY) Coriell Institute – Fibroblasts
GW08402 Sun et al., 2016
8402-iPSCs
Human: hDFN-iPSCs (XY) ThermoFisher: Human Dermal
Fibroblasts neonatal (HDFn)
C0045C. Bidinosti et al., 2016
hDFN-iPSCs
Human: transgenic H1-hESCs + dox inducible (i) Cas9 Ihry et al, 2018 H1-iCas9
Human: transgenic H1-hESCs + CAG-dCAS9-KRAB This paper HI-hESC CRISPRi
Human: transgenic hDFN-iPSCs + CAG-dCAS9-KRAB This paper HI-hDFN CRISPRi
HEK293T ATCC CRL-3216
Oligonucleotides
Spacer Sequence for synthetic crRNA: PMAIP1 crRNA 3
TCGAGTGTGCTACTCAACTC
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: PAWR crRNA 5
CGAGCTCAACAACAACCTCC
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: TP53 crRNA 1
GAAGGGACAGAAGATGACAG
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: TP53 crRNA 2
GAAGGGACAGAAGATGACAG
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: TP53 crRNA 4
GAGCGCTGCTCAGATAGCGA
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: P21 crRNA 1
AATGGCGGGCTGCATCCAGG
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: P21 crRNA 4
TCCACTGGGCCGAAGAGGCGG
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Spacer Sequence for synthetic crRNA: P21 crRNA 6
GGCGCCATGTCAGAACCGGC
Alt-R CRISPR-Cas9 crRNA,
2 nmol - IDT
N/A
Recombinant DNA
LentiCRISPR - Lentiviral backbone for CRISPR
nuclease interference spacer sequences cloning
pNGx-LV-g003 Plasmid backbone
from DeJesus et al., 2016
pNGx-LV-g003
LentiCRISPR - Lentiviral backbone for CRISPR
Genome-wide sgRNA library
pRSI16 lentiviral plasmid (Cellecta,
Mountain View, CA) Described by
DeJesus et al., 2016
N/A
pAAVS1-CAG-dCAS9-KRAB This paper Data S1
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Robert
Ihry (robert.ihry@novartis.com). Certain terms in existing license agreements may restrict our ability to transfer CRISPR/Cas9-related
reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Pluripotent Stem Cell lines
H1-hESCs (XY) (WA01-NIHhESC-10-0043) andH9-hESCs (XX) (NIHhESC-10-0062) were obtained fromWiCell. The following cell line
was obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research: GM08402. 8402-iPSCs
(XY) originated from GM08402 fibroblasts reprogrammed as described by Sun et al. (2016). hDFN-iPSCs (XY) were generated as
described by Bidinosti et al. (2016). hPSC lines were free of Myoplasma and tested using the Mycoalert Detection kit (Lonza).
SNP fingerprinting confirmed the identify of hPSC lines used. Karyotyping was performed by Cell Line Genetics (Madison, WI).
Large-scale culture of hPSCs
H1-hESCs with AAVS1 knock in of the iCas9 transgene were generated and cultured in TeSR-E8 media (STEMCELL TECH.-05940)
on vitronectin (GIBCO-A14700) coated plates as described by Ihry et al. (2018). Pilot studies with a sub-genome sgRNA library used a
total of 40 individual T225 flasks and was cumbersome (Ihry et al., 2018). Daily feeding and passaging in which multiple flask needed
to be pooledwas time consuming and increased the risk for contamination. Tominimize themanipulation required during feeding and
passaging we used 5-layer CellSTACKs. The vessels are large enough to contain an entire 45,000 sgRNA library at > 1000x coverage
per sgRNA at a seeding density of 21,000 cells/cm[2] (Seed 66 million cells for 1400x). In practical terms only 4 to 8 5-layer
CellSTACKs were growing at a given time during the month-long genome-scale CRISPR screen (Figure S1). Given the expense of
E8 media Penicillin-Streptomycin (pen/strep) at 100 U/mL was added as an additional insurance policy for the first screen at scale.
After running a lengthy genome-scale screen and becoming experienced with large-scale hPSC culture it is possible to run future
screens without pen/strep.
METHOD DETAILS
Genome Engineering
H1-hESCs expressing dox inducible (i) iCas9 were generated by Ihry et al. (2018). Dox treated H1-iCas9 cells were subjected to three
successive rounds of RNAimax delivery of the two-component synthetic crRNA/tracrRNA (IDT) pairs targeting PMAIP1, PAWR, P21
(CDKN1A) and TP53 as described by Ihry et al. (2018). PMAIP1, and PAWRwere transfected with a single sgRNAwhile TP53 and P21
were co-transfected with 3 crRNAs. CRISPR indel analysis detected efficient gene disruption for all three genes and was performed
as described by Ihry et al. (2018).
Continued
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Software and Algorithms
Pooled CRISPR – Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
Pooled CRISPR - DESeq2 v1.10.1, Love et al., 2014 https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
Pooled CRISPR - RSA release 1.8 Ko¨nig et al. 2007 https://admin-ext.gnf.org/
publications/RSA/
Pooled CRISPR - BAGEL Hart and Moffat, 2016 https://sourceforge.net/projects/
bagel-for-knockout-screens/
RNaseq - STAR aligner v2.5.1b Dobin et al., 2013 https://github.com/alexdobin/STAR/
releases/tag/2.5.1b
RNaseq - HTSeq-count v0.6.0 Anders et al., 2015 https://htseq.readthedocs.io/en/
master/index.html
RNaseq - RSEM v1.2.28 Li and Dewey, 2011 https://github.com/deweylab/
RSEM/releases/tag/v1.2.28
RNASeq - DESeq2 V 1.16.1 Love et al., 2014 https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
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PMAIP1 crRNA 3 TCGAGTGTGCTACTCAACTC
PAWR crRNA 5 CGAGCTCAACAACAACCTCC
TP53 crRNA 1 GAAGGGACAGAAGATGACAG
TP53 crRNA 2 GAAGGGACAGAAGATGACAG
TP53 crRNA 4 GAGCGCTGCTCAGATAGCGA
P21 crRNA 1 AATGGCGGGCTGCATCCAGG
P21 crRNA 4 TCCACTGGGCCGAAGAGGCGG
P21 crRNA 6 GGCGCCATGTCAGAACCGGC
lentiCRISPR packaging
For a one-layer CellSTACK 42million HEK293T (66,000 cells/cm2) were plated in 100 mL of media (DMEM +10% FBS + 1x NEAA, no
pen/strep). One day after seeding, cells were transfected with single lentiCRISPR plasmids in 6-well plates or pooled lentiCRISPR
plasmids in CellSTACKs. For a one-layer CellSTACK 102 uL of room temp TransIT (Mirus MIR 2700) and 3680 uL Opti-MEM (Invitro-
gen 11058021) were mixed incubated in a glass bottle for 5 minutes at room temp. 94.5 ug of Lentiviral Packaging Plasmid Mix
(Cellecta CPCP-K2A) and 75.6 ug of the lentiCRISPR plasmid library was added to the transfection mix and incubated for 15 minutes
at room temp. After incubation, themix was added to 100mL of freshmedia and the cells were fed. The next day the transfected cells
received 100 mL fresh media. After 3 days of viral production supernatants were filtered (.45uM corning 430516) and aliquoted in to
1ml tubes for storage at 80 C.
Large-scale transduction of hPSCs
We conducted a genome-scale CRISPR screen using a 91,726 sgRNA library (5 sgRNAs per gene, split into two sgRNA sub-pools
(DeJesus et al., 2016). We desired > 1000x coverage of each sgRNA to offset cell loss from double strand break (DSB)-induced
toxicity (Ihry et al., 2018). To screen a sufficient number of cells we infected hPSCs with lentiCRISPRs in 5-layer CellSTACKs. Cells
were infected at 0.5 MOI to ensure each cell was infected with no more than a single sgRNA. After puromycin selection cells were
expanded for one week without dox to be pelleted for DNA, banked or screened (Figures 1A and S1).
Pooled CRISPR screens rely on cells being efficiently transduced at less than or equal to 0.5 MOI. We developed a reverse trans-
fectionmethod for hPSCswithout polybrene that resulted in an efficient transduction with low volume exposure to HEK293T lentiviral
supernatants. LentiCRISPR plasmids expressed a constitutive RFP and puromycin resistance to mark and select for infected cells
respectively. Viral titer of the two45,000 sgRNA libraries expressing RFP in 6-well plates determined that less than 25 uL in 1.5mL of
media was required for 0.5 MOI. These calculations scaled appropriately in 5-layer cell stacks with 500 mL of media and approxi-
mately 50% of the cells were RFP positive in the absence of puromycin.
A genome-scale lentiCRISPR library targeting each gene 5 times has been split into 45,000 sub-pools (pool 1 and 2). To screen
at > 1000x per sgRNA, 264 million hPSCs are infected in 4x 5-layer CellSTACKS (12,720 cm2, 21,000 cells/ cm2). 2 stacks equal one
replicate. Cells are infected at 0.5 MOI to ensure only one sgRNA is expressed per cell (+sgRNA/puroR/RFP). After puromycin selec-
tion cells are expanded until confluent (4-6 days). At this point 40million cells (10million/ml) can be banked in 5ml cryovials for use at a
later date.
Banking lentiCRISPR infected hPSC library
One 5-layer cell stack was treated with 200 mL accutase that was evenly distributed among layers. After incubation at 37 C for
10minutes, accutase (GIBCO-A1110501) was neutralizedwith 200mL E8media. Cells were counted and pelleted to be resuspended
at a concentration of 10 million cells per ml in a solution of 40% Tet-free FBS (Seradigm #1500-500) and 10% DMSO (Sigma D2650)
and 50% E8 media. 4 mL aliquots were placed in 5 mL cryovials and frozen in a Mr. Frosty (Thermo Scientific 5100-0050) at 80 C
overnight before long-term storage in liquid nitrogen. Thawing of cells banked in 5ml cryovials showed an average viability around
85% for both lentiCRISPR pools. Viability was assayed using a Nexcelom Cellometer Auto 2000 and AO/PI (Nexcelom CS2-0106)
staining solution.
We tested the effect of freezing and thawing on the representation of the sgRNAs in the library by thawing the cell library at 2700x
(120million cells per 45k sub-pool) cells per sgRNA. Cells were thawed in a 37Cwater bath and transferred to a 50mL conical with E8
media and centrifuged at 300 g for 3 minutes. Pelleted cells were resuspended in E8 media and replated at a density of 40,000 to
60,000 cells/cm2. 3 cryovials with 120 million cells was thawed and plated on a 5-layer cell stack (120,000,000 /45,000 = 2700x).
After thawing and feeding the cells for two days, DNA was isolated and analyzed by NGS to measure the representation of each
sgRNA in the pool. Both day zero and freeze/thaw samples had an over 87% alignment of sequencing reads and fewer than 25
missing barcodes per replicate. Pearson correlation analysis allowed us to demonstrate that there was a high correlation between
the day zero samples and the freeze/thaw samples. Calculating normalized sgRNA counts revealed a strong correlation between
the cell library before (day 0) or after one freeze/thaw cycle (Figure 1B).
Pooled Mutagenesis (CRISPR nuclease/interference)
H1-hESCs expressing a constitutive (c) Cas9-KRAB knocked-in to the AAVS1 locuswere generated as described by Ihry et al. (2018).
The following lentiCRISPR were used to transduce iCas9 or cCas9-KRAB cells to generate mutant cell pools.
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CRISPR nuclease
PAWR sgRNA 1 TTTGGGAATATGGCGACCGG
PAWR sgRNA 2 GGTGGCTACCGGACCAGCAG
PAWR sgRNA 5 CGAGCTCAACAACAACCTCC
MAPT sgRNA 1 GAAGTGATGGAAGATCACGC
ACSL4 sgRNA TGGTAGTGGACTCACTGCAC
ARSH sgRNA GCAGCACCGTGGCTACCGCA
BMX sgRNA ATGAAGAGAGCCGAAGTCAG
BTK sgRNA GGAATCTGTCTTTCTGGAGG
GABRA3 sgRNA AAGGACTGACCTCCAAGCCC
GK sgRNA TAGAAAGCTGGGGCCTTGGA
NRK sgRNA CGCCTTCCTATTTCAGGTAA
TLR7 sgRNA CAGTCTGTGAAAGGACGCTG
CRISPR interference
Control-2 GACCGGAACGATCTCGCGTA
PAWR sgRNA 1 GGCGCGCTCGAGGACTCCAA
PAWR sgRNA 2 GTTGCAGGGTGGGGACCCGG
PAWR sgRNA 3 GCTGGCCGGTAGTGACTGGT
PAWR sgRNA 5 GGCTGCTGGCCGGTAGTGAC
OCT4 FACS-BASED screen
Cells were dissociated using accutase for 10min at 37C to create a single-cell suspensionwhichwas strained using a 40-micron filter
and was counted. After removing accutase, pelleted cells were resuspended in a volume of 1 million cells/mL for the staining pro-
tocol. For each replicate 55 million unsorted cells were frozen down prior to fixation. The remaining cells were fixed in 4% PFA in
PBS for 10 minutes at room temperature on a rocker. Cells were spun down at 300 RCF for 3 min between each subsequent solution
change. Cells were washed with 0.1% Triton-X in PBS after fixation and blocked in 2% goat serum, 0.01% BSA and 0.1% triton X in
PBS for 1hr at room temperature. Conjugated (AF488) primary antibodies specific to OCT4 (CST 5177) were diluted in blocking
solution (1:200) and incubated with cells on a rocker over night at 4 C. Prior to FACS analysis cells were resuspended in PBS at a
concentration of 30million cells/mL. A total of 1.2 billion cells (both replicates) were sorted into OCT4low (50million cells) andOCT4high
(61 million cells) populations using an ARIA III (BD).
DNA isolation and NGS libraries
For each replicate, 55 million cells (1200x) were pelleted and genomic DNA was isolated using QIAamp DNA Blood Maxi Kit
(QIAGEN 51194) as directed by manufacturer. Isolating genomic DNA from 4% PFA fixed cells was performed by utilizing phenol
chloroform extraction. Cells were resuspended in 500ul TNES (10mM Tris-Cl ph 8.0, 100mM NaCL, 1mM EDTA, 1% SDS) and incu-
bated overnight at 65 C. After allowing the samples to cool, 10ul of RNase A (QIAGEN 19101) and samples were incubated at 37 C for
30 minutes. Next, 10ul of proteinase K (QIAGEN 19133) and incubated for 1 hour at 45 C. Add 500ul of PCIA (Phenol;Cholorform;
Isoamyl alcohol ph 8) (Thermo 17908) and vortex. Spin samples in a centrifuge at max speed for 2 minutes. Transfer the aqueous
phase to 500ul of PCIA and vortex. Spin at max speed for 2 minutes. Transfer the aqueous phase to 450ul of chloroform and vortex.
Spin atmax speed for 2minutes. Transfer aqueous phase to 40ul of 3MNaAcOph 5.2. Add 1mL of 100%ethanol, mix and precipitate
DNA for 1 hour on ice. Spin at max speed for 2 minutes. Decant and wash with 1ml 70% ethanol. Spin at max speed for 1 minutes.
Decant and air dry the pellet. Resuspend in 50ul of nuclease free H20. PCR was performed using lentiCRISPR specific primers and
library construction and sequencing was performed as described by DeJesus et al. (2016).
mRNA expression
qPCR and RNA-seq analysis were performed as described by Ihry et al. (2018). Median TPM values for H1-hESCs are available upon
request. RNA-seq data for in 4 iPSC control lines subjected to NGN2 differentiation is available upon request but is restricted to the
expression for PAWR and PMAIP1.
Assaying sensitivity to DNA damage
Control and mutant iCas9 H1-hESCs expressing a MAPT targeting sgRNA were monitored daily post-media change using an
IncuCyte zoom (Essen Biosciences). At the onset of the experiment cells were plated at density of 10,500 to 21,000 cells/cm[2]
and cultured plus or minus dox for the duration. Confluence was calculated using the processing analysis tool (IncuCyte Zoom
Software).
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Assaying survival without ROCK inhibitor
Control and mutant iCas9 H1-hESCs were dissociated with accutase for 10 minutes. Flowmi 40-micron cell strainers (BEL-ART
H13680-0040) were used to ensure a uniform single-cell suspension prior to replating cells. Cells were plated at a density of
10,500 to 21,000 cells/cm[2] plus or minus thiazovivin (ROCK inhibitor, Selleckchem, S1459). Timelapse images were taken in
3 hr intervals using IncuCyte zoom (Essen Biosciences). The confluence processing analysis tool (IncuCyte Zoom Software) calcu-
lated confluency for each sample.
Immunofluorescence and Western Blotting
Immunofluorescence staining of fixed cells was performed as described by Ihry et al. (2018). Protein lysates were made by vortexing
cell pellets in RIPA buffer (Thermo Scientific 89901) supplemented with Halt protease inhibitor cocktail (Thermo Scientific 78430)
and phosphatase inhibitors (Thermo Scientific 1862495). Samples were incubated at 4C for 10 minutes before centrifugation at
14,000 x g for 10 minutes at 4C. Supernatants were transferred to new tubes and quantified using the BCA protein assay kit (Thermo
Scientific 23225) and a SpectraMax Paradigm (Molecular Devices) plate reader. Samples were prepared with NuPAGE LDS sample
buffer 4x (Invitrogen NP0008) and NuPAGE sample reducing agent (Invitrogen NP0009) and heated for 10 minutes at 70 C.
Chameleon Duo Pre-stained Protein Ladder (LiCOR P/N 928-60000) was loaded alongside 10 ug of protein per sample on a NuPAGE
4%–12% Bis-Tris Protein Gels, 1.5 mm, 10-well (Invitrogen NP0335BOX). Gel electrophoresis was performed at 150 V for 1hr in
NuPAGEMOPS SDS Running buffer (20X) (Invitrogen NP0001) using a XCell SureLock Mini-Cell (Thermo Scientific EI0002). Transfer
was performed using an iBlot 2 dry blotting system (Thermo IB21002 and IB23002) as described bymanufacturer. Blots were blocked
in TBS blocking buffer (LiCOR 927-50000) for 1 hour at room temperature. The blots were then incubated with primary antibodies
diluted in TBS over night at 4 C. Blots were washed 3X in PBST and incubated with secondary antibodies diluted in TBS for 2 hours
at room temperature. Blots were imaged using an Odyssey CLx (LiCOR).
Primary antibodies
Phallodin-647 (ThermoFisher Scientific A22287) - 1:40
SCRIB (Abcam ab36708) - 1:100 (IF)
PRKCZ (Abcam ab59364) - 1:100 (IF)
PAWR/PAR-4 (CST-2328) - 1:100 (IF)
Cleaved Caspase-3 Asp175 (CST-9661) - 1:200 (IF) 1:1000 (WB)
GAPDH (Enzo ADI-CSA-335-E) - 1:1000 (WB)
Secondary Antibodies
IRDye 800CW anti-rabbit (LiCOR 926-32211) - 1:5000
IRDye 680RD anti-mouse (LiCOR 926-68070) - 1:5000
AF488 conjugate Goat anti-Rabbit IgG (H+L) (ThermoFisher-A-11008) - 1:500
QUANTIFICATION AND STATISTIC ANALYSIS
Figures 1B and 7A
The scatterplot in 1B depicts the average normalized count values (n = 2 replicates) for sgRNA barcodes (91,000 sgRNAs) in two
conditionsmarked by the X- and y axis. The heatmap in 7A depicts Pearson correlation coefficients calculated using average normal-
ized sgRNA counts from Hart et al. (2015) and this study. 1B: The r-square values were calculated as the square of standard corre-
lation in R 7A: The r-square values were calculated as the square of standard correlation in R.
Figures 1D, 2A, and 6B
Redundant siRNA activity (RSA) analysis is a statistical method used to calculate a p values based on the activity ranked distribution
of all sgRNAs targeting a single gene (Ko¨nig et al., 2007) (https://admin-ext.gnf.org/publications/RSA/, https://admin-ext.gnf.org/
publications/RSA/RSA_tutorial.pdf). This probability-based method favors genes with multiple active sgRNAs over a single but
very active sgRNA. RSA scores each gene by identifying a bias in the distribution of sgRNAs targeting that gene. Two replicates
per condition were sequenced and the raw sgRNAs counts for the genome-wide library (91,000 sgRNAs) were used to calculate
log2(fold change) by DESeq2 (Love, Huber and Anders, 2014). Log2(fold changes) for the entire sgRNA library were used as the
ranked distribution for RSA analysis. In this study two independent replicates with high coverage (1000 cells per sgRNA) were cho-
sen because hPSC media is prohibitively expensive at genome-scale for the month-long screen.
Figure 1E
The BAGEL statistical model was used to calculate Bayes Factor scores and Precision Recall analysis (http://bagel-for-
knockout-screens.sourceforge.net/). Log2(Fold Change) of raw sgRNA counts were used as input to for BAGEL analysis.
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Figures 3B and 3E
Statistical analysis of relative expression values generated by qPCR for PMAIP1 (3B) P21 (3E) and FAS (3E) mRNAs was conducted
using PRISM software (version 7.0c). Relative expression values for control and treated samples were tested for statistical differ-
ences by conducting an ordinary an unpaired two tailed t test with equal variance. n = 3 for control and treated mRNA samples iso-
lated from 3 independent wells are plotted as individual dots. Bars indicate mean and error bars depict standard deviation. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
Figure 3A and S4F
Differential gene expression was performed in R with DESeq2 which is suitable for studies with three replicates (n = 3), andmaintains
high precision and sensitivity (Love, Huber and Anders, 2014). Gene counts are normalized for library size using the geometric mean
and modeled with a negative binomial distribution. RNA was isolated from 1-4 independent samples for both control and Ngn2
neuronal samples in different hPSC backgrounds (H1-hESCs (n = 1), H9-hESCs (n = 3), 8402-iPSCs (n = 3) and HDFn-iPSCs (n = 4)).
DATA AND SOFTWARE AVAILABILITY
RNaseq data in hPSCs and Ngn2 neurons is limited to the expression of PMAIP1 and PAWR and is available upon request. Normal-
ized sgRNA counts, Log2(fold changes) andRSA analysis for pooled CRISPR screens in H1-hESCs are available in Tables S1, S2, S3,
S5 and S8. Pooled CRISPR screening data in cancer cell lines is limited to Log2(fold changes) for PMAIP1 sgRNAs and is available
upon request. RNA-seq data processing and pooled CRISPR NGS were conducted using open source software as indicated in the
key resources table.
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